Blood thinner after stroke surgery shows promise in large trial
NCT ID NCT06265051
First seen Sep 30, 2025
Summary
This study tested whether giving the blood-thinning drug tirofiban after mechanical clot removal improves outcomes in people with acute ischemic stroke. Over 1,300 participants were randomly assigned to receive tirofiban or a placebo. The goal was to see if tirofiban could reduce disability and prevent re-clotting without causing dangerous bleeding.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 450001, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tirofiban (a blood-thinning drug given through a vein)
What this could lead to
If it works, this could provide a new standard treatment to improve recovery and reduce disability after a severe stroke.
What could go wrong
This is a mid-stage trial, so results may not confirm benefit. Tirofiban increases bleeding risk, which could cause harm in some patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.